044 FSFI Assessment of Minimally Invasive, Fractional CO2 Laser Treatment for Vulvovaginal Atrophy and Dyspareunia

A Prospective non-randomized, non-controlled design to evaluate the Edge One CO2 laser transvaginal procedure for treatment of VulvaVaginal Atrophy (VVA) and sexual dysfunction using the Female Sexual Function Index (FSFI) for objective assessment. The data was obtained from thirty three 14 female subjects between the ages of 42-83 presenting with vulvovaginal atrophy or dyspareunia at baseline who completed three treatments and one follow-up visit were analyzed. Vulvovaginal atrophy was determined by self-reported perceptions of vaginal dryness and dyspareunia or inability to participate in sexual activity due to pain or discomfort. A history and physical exam was performed on all patients before treatment. All patients had a Papanicolou smear cytology within 24 months prior to treatment showing no dysplasia. The main exclusion criteria included previous reconstructive vaginal laxity with pelvic prolapse extending beyond the vaginal opening using the Baden-Walker Grade 2 or Stage 2 Pelvic Organ Prolapse (<= 1 cm past hymen).